Peringatan Keamanan

Oral LD50 Rat = 184 mg/kg, Oral LD50 Mouse = 322 mg/kg

Nicardipine

DB00622

small molecule approved investigational

Deskripsi

A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. PubChem

Struktur Molekul 2D

Berat 479.525
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 8.6 hours
Volume Distribusi * 8.3 L/kg
Klirens (Clearance) * 0.4 L/hr?kg [Following infusion]

Absorpsi

While nicardipine is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady state.

Metabolisme

Nicardipine HCl is metabolized extensively by the liver.

Rute Eliminasi

Nicardipine has been shown to be rapidly and extensively metabolized by the liver.

Interaksi Makanan

2 Data
  • 1. Avoid grapefruit products.
  • 2. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

1986 Data
Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Nicardipine is combined with Duloxetine.
Levodopa The risk or severity of hypotension and orthostatic hypotension can be increased when Nicardipine is combined with Levodopa.
Risperidone Nicardipine may increase the hypotensive activities of Risperidone.
Reserpine Reserpine may decrease the excretion rate of Nicardipine which could result in a higher serum level.
Ursodeoxycholic acid Ursodeoxycholic acid may decrease the excretion rate of Nicardipine which could result in a higher serum level.
Cholic Acid Cholic Acid may decrease the excretion rate of Nicardipine which could result in a higher serum level.
Simeprevir Simeprevir may decrease the excretion rate of Nicardipine which could result in a higher serum level.
Lenvatinib Lenvatinib may decrease the excretion rate of Nicardipine which could result in a higher serum level.
Valinomycin Valinomycin may decrease the excretion rate of Nicardipine which could result in a higher serum level.
Olmesartan Olmesartan may decrease the excretion rate of Nicardipine which could result in a higher serum level.
Pralsetinib The serum concentration of Pralsetinib can be increased when it is combined with Nicardipine.
Ceritinib Nicardipine may increase the bradycardic activities of Ceritinib.
Ruxolitinib Ruxolitinib may increase the bradycardic activities of Nicardipine.
Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Nicardipine.
Amifostine Nicardipine may increase the hypotensive activities of Amifostine.
Diazoxide Diazoxide may increase the hypotensive activities of Nicardipine.
Methylphenidate Methylphenidate may decrease the antihypertensive activities of Nicardipine.
Dexmethylphenidate Dexmethylphenidate may decrease the antihypertensive activities of Nicardipine.
Obinutuzumab Nicardipine may increase the hypotensive activities of Obinutuzumab.
Pentoxifylline Pentoxifylline may increase the hypotensive activities of Nicardipine.
Rituximab Nicardipine may increase the hypotensive activities of Rituximab.
Desmopressin Desmopressin may decrease the antihypertensive activities of Nicardipine.
Doxapram Doxapram may decrease the antihypertensive activities of Nicardipine.
Phenmetrazine Phenmetrazine may decrease the antihypertensive activities of Nicardipine.
Dopamine Dopamine may decrease the antihypertensive activities of Nicardipine.
Epicaptopril Epicaptopril may decrease the antihypertensive activities of Nicardipine.
1-benzylimidazole 1-benzylimidazole may decrease the antihypertensive activities of Nicardipine.
Tyramine Tyramine may decrease the antihypertensive activities of Nicardipine.
Moxisylyte Moxisylyte may decrease the antihypertensive activities of Nicardipine.
Atipamezole Atipamezole may decrease the antihypertensive activities of Nicardipine.
Idazoxan Idazoxan may decrease the antihypertensive activities of Nicardipine.
Tramazoline Tramazoline may decrease the antihypertensive activities of Nicardipine.
Fenozolone Fenozolone may decrease the antihypertensive activities of Nicardipine.
Xenon Xenon may decrease the antihypertensive activities of Nicardipine.
Buflomedil Buflomedil may decrease the antihypertensive activities of Nicardipine.
Mefenorex Mefenorex may decrease the antihypertensive activities of Nicardipine.
Quinoline Yellow WS Quinoline Yellow WS may decrease the antihypertensive activities of Nicardipine.
Dutasteride Dutasteride may decrease the antihypertensive activities of Nicardipine.
Naxitamab Naxitamab may decrease the antihypertensive activities of Nicardipine.
Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Nicardipine.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Nicardipine.
Everolimus The metabolism of Everolimus can be decreased when combined with Nicardipine.
Flibanserin The metabolism of Flibanserin can be decreased when combined with Nicardipine.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Nicardipine.
Ivabradine The metabolism of Ivabradine can be decreased when combined with Nicardipine.
Ivacaftor The metabolism of Ivacaftor can be decreased when combined with Nicardipine.
Lurasidone The metabolism of Lurasidone can be decreased when combined with Nicardipine.
Naloxegol The metabolism of Naloxegol can be decreased when combined with Nicardipine.
Olaparib The metabolism of Olaparib can be decreased when combined with Nicardipine.
Ranolazine The metabolism of Ranolazine can be decreased when combined with Nicardipine.
Sonidegib The metabolism of Sonidegib can be decreased when combined with Nicardipine.
Avanafil The metabolism of Avanafil can be decreased when combined with Nicardipine.
Eplerenone The metabolism of Eplerenone can be decreased when combined with Nicardipine.
Aclidinium The risk or severity of adverse effects can be increased when Nicardipine is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Nicardipine.
Mirabegron The risk or severity of urinary retention can be increased when Nicardipine is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Nicardipine is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Nicardipine.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Nicardipine.
Tiotropium The risk or severity of adverse effects can be increased when Nicardipine is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Nicardipine is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Nicardipine is combined with Umeclidinium.
Colchicine The metabolism of Colchicine can be decreased when combined with Nicardipine.
Fentanyl The risk or severity of adverse effects can be increased when Nicardipine is combined with Fentanyl.
Iloperidone The risk or severity of hypotension can be increased when Nicardipine is combined with Iloperidone.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Nicardipine.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Nicardipine.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Nicardipine.
Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Nicardipine.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Nicardipine.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Nicardipine.
Cimetidine The serum concentration of Nicardipine can be increased when it is combined with Cimetidine.
Clopidogrel The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nicardipine.
Efavirenz The serum concentration of Nicardipine can be decreased when it is combined with Efavirenz.
Melatonin The therapeutic efficacy of Nicardipine can be decreased when used in combination with Melatonin.
Nafcillin The therapeutic efficacy of Nicardipine can be decreased when used in combination with Nafcillin.
Nitroprusside Nicardipine may increase the hypotensive activities of Nitroprusside.
Dantrolene The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Nicardipine.
Lithium citrate The risk or severity of adverse effects can be increased when Nicardipine is combined with Lithium citrate.
Lithium carbonate The risk or severity of adverse effects can be increased when Nicardipine is combined with Lithium carbonate.
Lithium hydroxide The risk or severity of adverse effects can be increased when Nicardipine is combined with Lithium hydroxide.
Dapoxetine Dapoxetine may increase the orthostatic hypotensive activities of Nicardipine.
Alprazolam The metabolism of Alprazolam can be decreased when combined with Nicardipine.
Mifepristone The serum concentration of Nicardipine can be increased when it is combined with Mifepristone.
Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Nicardipine.
Glycopyrronium The risk or severity of adverse effects can be increased when Nicardipine is combined with Glycopyrronium.
Carvedilol Nicardipine may increase the hypotensive activities of Carvedilol.
Warfarin The serum concentration of Warfarin can be increased when it is combined with Nicardipine.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Nicardipine.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Nicardipine.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Nicardipine.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Nicardipine.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Nicardipine.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Nicardipine.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Nicardipine.
Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Nicardipine.
Boceprevir The serum concentration of Nicardipine can be increased when it is combined with Boceprevir.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Nicardipine is combined with Botulinum toxin type A.
Glucagon Nicardipine may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Nicardipine may increase the anticholinergic activities of Sulpiride.

Target Protein

Voltage-dependent L-type calcium channel subunit alpha-1C CACNA1C
Voltage-dependent L-type calcium channel subunit beta-2 CACNB2
Voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1
Voltage-dependent L-type calcium channel subunit alpha-1D CACNA1D
Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A PDE1A
Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B PDE1B
Alpha-1A adrenergic receptor ADRA1A
Alpha-1B adrenergic receptor ADRA1B
Alpha-1D adrenergic receptor ADRA1D
Muscarinic acetylcholine receptor M1 CHRM1
Muscarinic acetylcholine receptor M2 CHRM2
Muscarinic acetylcholine receptor M3 CHRM3
Muscarinic acetylcholine receptor M4 CHRM4
Muscarinic acetylcholine receptor M5 CHRM5
Voltage-dependent calcium channel CACNG1
Voltage-dependent T-type calcium channel subunit alpha-1G CACNA1G
Voltage-dependent T-type calcium channel subunit alpha-1H CACNA1H
Voltage-dependent T-type calcium channel subunit alpha-1I CACNA1I
Calmodulin CALM1

Referensi & Sumber

Synthesis reference: Takashi Sonobe, Hiroitsu Kawata, Masayoshi Aruga, Tadayoshi Ohmura, Satoru Yoneya, Chiharu Yamada, Yukio Kubota, "Composition for long acting nicardipine preparation and process of producing the composition." U.S. Patent US4758437, issued March, 1979.

Contoh Produk & Brand

Produk: 94 • International brands: 0
Produk
  • Cardene
    Injection • 2.5 mg/1mL • Intravenous • US • Approved
  • Cardene
    Capsule, extended release • 30 mg/1 • Oral • US • Approved
  • Cardene
    Capsule, extended release • 45 mg/1 • Oral • US • Approved
  • Cardene
    Capsule, extended release • 60 mg/1 • Oral • US • Approved
  • Cardene
    Capsule, gelatin coated • 20 mg/1 • Oral • US • Approved
  • Cardene
    Capsule, gelatin coated • 30 mg/1 • Oral • US • Approved
  • Cardene
    Injection • 2.5 mg/1mL • Intravenous • US • Approved
  • Cardene 20mg Capsules
    Capsule • 20 mg / cap • Oral • Canada • Approved
Menampilkan 8 dari 94 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul